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Abstract
Background: Over 350 million people worldwide are infected with hepatitis B virus (HBV), a major cause of liver failure and
hepatocellular carcinoma. Current therapeutic agents are highly effective, but are also associated with development of viral
resistance. Therefore, strategies for identifying other anti-HBV agents with specific, but distinctive mechanisms of action are
needed. The human La (hLa) protein, which forms a stabilizing complex with HBV RNA ribonucleoprotein to promote HBV
replication, is a promising target of molecular therapy.
Aims: This study aimed to discover novel inhibitors of hLa that could inhibit HBV replication and expression.
Methods: A multistage molecular docking approach was used to screen a Specs database and an in-house library against
hLa binding sites. Sequential in vitro evaluations were performed to detect potential compounds with high scores in
HepG2.2.15 cells.
Results: Of the 26 potential compounds with high scores chosen for experimental verification, 12 had HBV DNA inhibition
ratios of less than 50% with P,0.05. Six had significant inhibition of HBV e antigen (HBeAg) levels, and 13 had significant
inhibition of HBV surface antigen (HBsAg) levels by in vitro assays. Compounds HBSC-11, HBSC-15 and HBSC-34 (HBSC is
system prefix for active compounds screened by the library) were selected for evaluation. HBSC-11 was found to have an
obvious inhibitory effect on hLa transcription and expression.
Conclusions: Our findings suggest that anti-HBV activity of HBSC-11 may be mediated by a reduction in hLa levels. In
addition, our data suggest the potential clinical use of hLa inhibitors, such as HBSC-11, for treating HBV infection.
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Introduction
More than 350 million people worldwide are chronically
infected by the hepatitis B virus (HBV), increasing their risk of
developing chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma [1]. Antiviral resistance and side effects have limited the
utility of currently approved therapies. HBV, a member of the
hepadnaviridae family, is a non-cytopathic virus with a 3.2 kb
circular DNA genome. After conversion into covalently closed
circular DNA in the host cell nucleus, this genome serves as a
template for transcription of all viral RNAs [2].
The potential of small RNA interference to induce post-
transcriptional down-regulation of HBV RNA in a stable HBV-
expressing cell line, HepG2.2.15, has been highlighted in the past
[3]. The human La (hLa) protein, in concert with additional trans-
acting factors, forms an HBV RNA ribonucleoprotein complex
stabilizing HBV RNA [2] by binding at a site that is located within
the viral RNA between nucleotides 1275 and 1291 [4,5]. Protein
hLa is a 47 kDa phosphoprotein predominantly localized in the
nucleus, and was originally identified as a major target of the
autoimmune response in patients suffering from the autoimmune
diseases Sjogren’s syndrome and systemic lupus erythematosus [6].
Since then, it has been characterized as a conserved RNA-binding
protein that interacts specifically with oligouridylate stretches in
the RNA [7].
The hLa protein has been shown to be associated with all RNA
polymerase III transcripts that carry the UUUOH sequence as the
transcription termination signal. Therefore, this protein is believed
to play a central role in the metabolism of these RNAs, possibly
acting as a molecular chaperone to stabilize and support RNAs for
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suggested to stabilize various other critical human RNAs, such as
histone, and RNAs of pathogens that have taken up residence in
the host cell, such as hepatitis C and B virus [4,9,10].
Among the different La proteins identified in a variety of
organisms, the N-terminal sequence is highly conserved [11]. The
three-dimensional (3D) structure of the hLa-RNA domain was
determined by X-ray crystallography [7]. In addition, studies have
elucidated the structures of hLa-RNA complex with the highly
conserved N-terminus, the La motif, the central RNA recognition
motifs (RRM), the C-terminal RRM (NRE), and the important
serine residue (Ser) 366 [6,7].
The objective of this study was to identify novel classes of
compounds capable of inhibiting hLa and determine their
potential for blocking HBV replication and expression.
Results
Computational modeling and virtual screening
Grid-based ligand docking from energetics (GLIDE) software
[12] (Schrodinger, Portland, OR) was used for computational
modeling and virtual screening based on the X-ray crystal
structure of the human La-RNA complex [7] (2VOD in the
Protein Data Bank, 2.1 A ˚). In preparation for docking, RNA was
removed and only one of the two symmetrical monomers (chain A)
was used as template (Figure 1). To validate the docking approach,
the U-2 nucleotide, which bound most deeply into the RNA
groove of the La protein, was extracted from the crystal structure
of chain A and used to perform docking. As expected, the optimal
docking pose closely reproduced the X-ray crystal structure (data
not shown). Three-dimensional structures of compounds from the
Specs chemical library were downloaded and processed with
LigPrep software (obtained from Schrodinger). Each chemical
structure (for small molecules) was docked into the U-2 nucleotide
binding site using GLIDE 5.5, and the Glide scoring function (G-
Score) was used to rank these final poses for all compounds in
decreasing order. The binding poses of the top 30 compounds
were stored for visual inspection of the docking geometry to avoid
unreasonable interactions. Finally, 26 of the 30 compounds were
selected for evaluation of inhibition of HBV and effects on hLa
expression.
Biological evaluations
To screen the anti-HBV activity of the 26 potential compounds
from the database, we measured their capacities to inhibit HBV
DNA replication and HBV e antigen (HBeAg) and HBV surface
antigen (HBsAg) levels in the HepG2.2.15 cell line. This well-
established cell line is permanently transfected with a plasmid
containing two head-to-tail dimers of the HBV genome, and
constitutively expresses HBV genes. Therefore, cultured
HepG2.2.15 cells can not only release high levels of HBsAg and
HBeAg into the media, but also support the assembly and
secretion of replicative intermediates of HBV DNA and Dane
particles [13]. Baseline virion DNA levels in cell culture
supernatants were measured to confirm that the HepG2.2.15 cells
were stably expressing HBV particles. The potential effect of
HBSC compounds on cell viability was evaluated by MTT assays,
and flow cytometry. Little difference in apoptosis or surviving cell
numbers was observed 24 h after treatment with HBSC
compounds when compared to controls (Figures 2A and B).
Results showed that the average quantity of HBV DNA was 10
6
copies/mL and HBsAg and HBeAg reactivity was strongly
positive. From the screening, 12 compounds were found to be
capable of inhibiting HBV DNA replication with ratio less than
50% (Figure 3A: HBSC-4 vs Control=27.18% vs 100%,
P=0.0025; HBSC-11 vs Control=32.59% vs 100%, P=0.0008;
HBSC-13 vs Control=27.75% vs 100%, P=0.0215; HBSC-14 vs
Control=11.06% vs 100%, P=0.0002; HBSC-15 vs Control=
20.44% vs 100%, P=0.0006; HBSC-16 vs Control=27.06% vs
100%, P=0.0207; HBSC-17 vs Control=30.06% vs 100%,
P=0.0022; HBSC-19 vs Control=31.20% vs 100%, P=0.0010;
HBSC-21 vs Control=22.37% vs 100%, P=0.0127; HBSC-22 vs
Control=25.20% vs 100%, P=0.0057; HBSC-25 vs Control=
11.71% vs 100%, P=0.0014; HBSC-34 vs Control=17.07% vs
100%, P=0.0006; siRNA vs Control=20.62% vs 100%, P=
0.0004), while 6 compounds resulted in significantly decreased
levels of HBeAg (Figure 3B: HBSC-1 vs Control=62.57% vs
100%, P=0.0270; HBSC-5 vs Control=60.59% vs 100%, P=
0.0193; HBSC-11 vs Control=49.89% vs 100%, P=0.0178;
HBSC-15 vs Control=58.04% vs 100%, P=0.0209; HBSC-27 vs
Control=68.35% vs 100%, P=0.0389; HBSC-34 vs Control=
69.05% vs 100%, P=0.0247; siRNA vs Control=51.37% vs
100%, P=0.0380) and 13 compounds resulted in significantly
decreased the levels HBsAg (Figure 3C: HBSC-1 vs Control=
70.60% vs 100%, P=0.0274; HBSC-4 vs Control=73.96% vs
100%, P=0.0358; HBSC-11 vs Control=62.52% vs 100%, P=
0.0353; HBSC-13 vs Control=66.69% vs 100%, P=0.0257;
HBSC-15 vs Control=83.02% vs 100%, P=0.0425; HBSC-19 vs
Control=72.62% vs 100%, P=0.0434; HBSC-20 vs Control=
81.97% vs 100%, P=0.0097; HBSC-22 vs Control=73.97% vs
100%, P=0.0486; HBSC-25 vs Control=76.75% vs 100%, P=
0.0393; HBSC-26 vs Control=82.50% vs 100%, P=0.0218;
HBSC-28 vs Control=73.41% vs 100%, P=0.0375; HBSC-31 vs
Control=74.96% vs 100%, P=0.0434; HBSC-34 vs Control=
81.41% vs 100%, P=0.0303; siRNA vs Control=80.58% vs
100%, P=0.0137).
Of the 26 selected compounds, only HBSC-11, HBSC-15 and
HBSC-34 were found to significantly decrease HBeAg, HBsAg
and HBV DNA levels (Figures 3A–C). Therefore, these three
Figure 1. RNA binding pocket of the human La protein. All
crystallographic water molecules were removed from the coordinate
set, and missing resides were repaired in the Maestro v7.5 molecular
modeling platform. Oxygen atoms are shown in red and nitrogen atoms
in blue. Carbon atoms of RNA are shown in green. Carbon atoms of
protein are shown in gray. Key residues of RNA binding sites are shown
as sticks and are labeled. Figures were generated by the PyMol
molecular visualization system (www.pymol.org).
doi:10.1371/journal.pone.0036363.g001
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hLa levels in HepG2.2.15 cells. Finally, only one compound,
HBSC-11, was shown to have significant inhibitory effects on hLa
expression, as evidenced by Western blotting (Figure 3D, HBSC-
11 vs Untreated cells=20.42% vs 100%, P=0.0069; siRNA vs
Untreated cells=28.59% vs 100%, P=0.0302) and qRT-PCR
(Figure 3E, HBSC-11 vs Untreated cells=29.73% vs 100%,
P=0.0217; siRNA vs Untreated cells=19.42% vs 100%,
P=0.0116).
Binding mode analyses of HBSC compounds
To gain insight into the mechanism by which HBSC
compounds affect the biological function of the La protein, we
carried out docking simulation to evaluate binding of the HBSC
compounds to human La protein. The results showed that HBSC
compounds enter a pocket composed of Gln20, Tyr23, Arg57,
Leu124, Asn139 and Ile140 (Figure 4A). HBSC-11 was found to
form two hydrogen bonds with the nitrogen atom of the main
chain of Asn139 and Ile140. Figure 4B shows that HBSC-15
formed two hydrogen bonds with the nitrogen atom of the side
chains of Gln20 and Arg57. Figure 4C shows that HBSC-34
formed one hydrogen bond with the nitrogen atom of the side
chain of Arg57. The deduced chemical formula and spatial
structure of these compound candidates are shown in Figure 5.
Typically, favorable functional groups such as sulfonyl, carboxyl
and hydroxyl were found in all 26 of the best scoring compounds
from the screening process.
Discussion
Currently, two major classes of agents are utilized in the therapy
of HBV infection: the interferon and the nucleoside analogues
[14], both of which are effective for viral suppression, but do not
result in high rates of sustained viral response. In addition, the
emergence of drug-resistant HBV strains may limit the long-term
therapeutic potential of nucleoside analogues. Therefore, the
development of novel antiviral drug targets is warranted.
The La protein is a multifunctional RNA-binding protein,
which has been implicated in the stabilization of HBV RNA [4].
La binds to a small RNA element [2,4,5] embedded in the
posttranscriptional regulatory element [15] that protects viral
RNA against endoribonucleolytic cleavage events [10]. In the case
of HBV, hLa in concert with additional transacting factors form
an HBV RNA ribonucleoprotein complex that stabilizes HBV
RNA [2]. Previous studies have demonstrated that La depletion by
RNA interference negatively affects HBV expression [16] and
down regulates HBV mRNA levels in HepG2.2.15 cells, which
supports the concept that La plays a role in the HBV viral life cycle
[17]. It is possible that La may be a potential drug target for
controlling HBV gene expression.
Figure 2. Cell viability assays after exposure to candidate compounds. Changes in cell numbers were measured by MTT assays. Cells were
collected after 24 h of treatment with 50 mM inhibitors. Induction of cell apoptosis (rh Annexin V/FITC) was determined according to the
manufacturer’s instructions. Differences in (A) apoptosis or (B) surviving cell numbers were observed 24 h after treatment with HBSC compounds
compared to controls.
doi:10.1371/journal.pone.0036363.g002
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identification of novel effective inhibitors [18]. Although no
similar computational approach has been reported in the literature
for identifying inhibitors of La in HBV, there have been many
reports on inhibitors of hepatitis C virus nonstructural protein 3
(HCV NS3) helicase/protease that have been identified by virtual
screening using the program DOCK [19–21].
Here, for the first time, we have demonstrated the feasibility of
using X-ray crystallographic data and computational modeling as
a basis for a structure-based virtual screening to identify chemical
inhibitors of La. Our novel strategy used large-scale structure-
based computational analysis followed by a series of in vitro
evaluations. On the basis of structural analysis of hLa, two
separate RRM binding sites were targeted. Both sites have known
competitive inhibitors. Moreover, RRM has been characterized as
an efficient submicromolar competitive inhibitor of this hLa. In
addition, the structural similarity of the inhibitors to the RRM
strongly suggests their ability to interact with the RRM pocket.
Therefore, on the basis of the specific structural interactions of
RRM, we sought inhibitory candidates directed against these
target sites.
Our virtual screening approach was based on initial high-
throughput docking calculations that were performed on a library
of more than 300,000 commercially available compounds. Using a
personal computer (PC) grid to harness the computing power of
our university’s PCs, we were able to perform these calculations
without prior focusing of the compound library. After the
compounds had been docked, compound poses were refined and
promising candidates were assayed in vitro. Insights from these
assays, combined with pharmacophoric searches based on the
predicted binding site, were then used to select further compounds
for follow-up testing.
Amino acid residues located within 12 A ˚ from Tyr23 in the
center of the RNA groove of the La protein were defined as part of
the binding site for docking studies. However, the RNA binding
site is rather shallow and solvent-exposed, so that molecules
interacting firmly with this site are difficult to find. The second site
binds the C-terminal RRM, which invokes problems of specificity
and off-target activity. Searching for new La-RNA binding site
inhibitors, we carried out a virtual screening campaign and
identified a La-RNA binding complex as the most potent and
optimizable hit. Until now, there have been no reports on a La
autoantigen specific inhibitor. Therefore, no proper control was
available to identify the function of new inhibitors. To solve this
problem, we chose the compounds with high scores (calculated
from the Glide software) to identify inhibitors with the highest
potential for targeting the La-RNA binding site. We utilized hLa
siRNA to compare the inhibition capacity of the selected
compound as our previous research [16].
From the viral expression assays, three compounds that
exhibited significant decreases in HBV DNA, HBeAg and HBsAg
levels were selected for further study. We analyzed the structure of
these three compounds, and found that two of them had similar
core structures and complicated three-domain structures. Among
the three compounds, only one, HBSC-11, appeared to have a
siRNA effect, as evidenced by significantly reduced La levels in
treated HepG2.2.15 cells. HBSC-11 is a a pyrazolo and pyridine
compound with the chemical name of methyl pyrazolo [1,5-a]
pyridine-2-carboxylate. This is a low molecular weight compound
with a simple structure that is easy to synthesize. Further study on
derivatives of this compound is warranted.
In conclusion, using virtual high-throughput screening, we have
discovered a new La inhibitor. Cell viability and siRNA assays
indicated that HBSC-11 is well accommodated. Docking modeling
revealed a potential binding pocket adjacent to the La-RNA site in
the RRM domain. Moving away from the endogenous binding
pocket allows for identification of residues that are less conserved
and may induce some selectivity among La inhibitors. These
observations have led us to investigate a new series of HBSC-11
derivatives and open the door for discovery of additional specific
inhibitors targeting La.
Materials and Methods
Protein preparation
The crystal structure of human La protein, previously
determined by Curry et al. [7], was retrieved from the Protein
Data Bank (PDB entry: 2VOD). Residues located within 12 A ˚
from Tyr23 in the center of the RNA groove of the La protein
were defined as the binding pocket for docking studies. All
crystallographic water molecules were removed from the coordi-
nate set, and missing resides were repaired using the Maestro v7.5
molecular modeling platform (Schrodinger, Inc.) [22].
Grid-based ligand docking from energetics (GLIDE)
Glide calculations were performed with Maestro v7.5. Hydro-
gen atoms and charges were added during a brief relaxation that
was performed using the Protein Preparation module in Maestro
with the ‘‘preparation and refinement’’ option. A restrained partial
minimization was terminated when the root-mean-square devia-
tion (rmsd) reached a maximum value of 0.3 A ˚, in order to relieve
steric clashes. The grid-enclosing box was centered on the oxygen
atom of the side chain of Tyr23 and defined so as to enclose
residues located within 14 A ˚ from the center of RNA groove. A
scaling factor of 1.0 was set to the van der Waals (VDW) radii of
the receptor atoms with partial atomic charges of less than 0.25. In
the docking process, standard precision (SP) and extra precision
(XP) docking were respectively adopted to generate the minimized
pose, while the Glide scoring function (G-Score) was used to select
the final three poses for each ligand. The docking simulations were
performed in parallel on a Dell Cluster server.
Virtual screening
Virtual screening of large chemical databases is a successful
approach for lead identification. Here, both Specs database
(http://www.specs.net/) and an in-house generated compound
library were employed to identify potential inhibitors of hLa.
In vitro evaluation
Cell culture. The human hepatoblastoma HepG2.2.15 [13],
a stable HBV-expressing cell line, was maintained in our lab
according to the method described by Zhang et al [16]. Briefly,
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco BRL, Gaithersburg, MD, USA) supplemented with
Figure 3. In vitro evaluations of HBSC compounds. HBV DNA levels were detected by FQ-PCR, and HBeAg and HBsAg levels were analyzed by
MEIA assays. hLa transcription and expression were detected by qRT-PCR and Western Blotting. (A) 12 compounds exhibited active inhibition of HBV
DNA replication and (B) 6 compounds exhibited active inhibition of HBeAg expression and (C) 13 compounds decreased the levels of HBsAg
expression and (D) 1 compound (HBSC-11) showed significant inhibition of hLa protein levels on Western blots. (E) 1 compound (HBSC-11) down-
regulated the hLa mRNA levels, as compared with that produced by the siRNA.
doi:10.1371/journal.pone.0036363.g003
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(Gibco BRL, Gaithersburg, MD, USA) , 100 U/mL penicillin,
and 100 mg/mL streptomycin (Gibco BRL, Gaithersburg, MD,
USA) at 37uC in a humidified atmosphere containing 50 mL/L
CO2. For experiments, 348 mg/mL G418 sulfate (Sigma-Aldrich,
St. Louis, MO, USA) was added to the medium. To assess cell
growth and viability, equal volumes of cell suspension and 0.4%
trypan blue solution were mixed and placed on a hemocytometer
for counting. Only cells with a viability of .85% were used for
further analysis.
Evaluation of potential inhibitors. Inhibitors were
dissolved in dimethyl sulfoxide (DMSO) (,0.5% volume of total
medium; Amresco, Solon, OH, USA) and then sterilized by
filtration through a 0.22 mm filter. Cells were treated for 24 h with
inhibitors at final concentrations of 50 mM each. All cell
treatments were conducted in triplicate, and control cells were
treated with equal amounts of the DMSO solvent alone under
identical conditions.
Cell viability assays. The changes in cell numbers were
detected by 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di- phenyte-
trazoliumromide (MTT) (Amresco, Solon, OH, USA) assay after
24 h exposure to various inhibitors or vehicle controls. Plates were
incubated at 37uC and 5% CO2 in a humidified cell culture
incubator. MTT (final concentration of 0.5 mg/mL) was added to
each well at 21 h and incubation continued for 3 h, after which
0.2 mL of acidified isopropanol was added to each well to dissolve
the MTT formazan [23]. Each experiment was repeated in
triplicate. Absorbance of MTT formazan was measured at 572 nm
and 690 nm. The corrected absorbance was determined by
subtracting the 690 nm value from the 572 nm value. Cells were
collected after 24 h of treatment with 50 mM inhibitors, and
induction of cell apoptosis (rh Annexin V/FITC) was determined
according to the manufacturer’s instructions (Beijing 4A Biotech
Co. Ltd., Beijing, China).
Detection of HBV expression. After treatment with
inhibitors for 24 h, culture supernatants of HepG2.2.15 cells
were collected. Extracellular HBV DNA was assayed by
fluorogenic quantitative polymerase chain reaction (FQ-PCR),
according to the manufacturer’s instructions (Da An Gene Co.
Ltd., Sun Yat-sen University, Guangzhou, China). The assay was
capable of quantifying HBV DNA with a theoretical lower limit of
detection of 5 genome equivalents per mL of supernatant. The
extracellular levels of HBV HBsAg and HBeAg produced from
HepG2.2.15 cells were measured using the ELISA kit according to
the manufacturer’s instructions (Beijing Bioneovan Co.,Ltd,
Beijing, China). Samples were considered reactive for HBsAg or
HBeAg, respectively, if the values of the sample rate/index
calibrator mean rate (S/N) was greater than or equal to 2.0, and
value of the sample rate/cut off rate (S/CO) was greater than or
equal to 2.1.
siRNA assay. According to the hLa mRNA sequence
(NM003142) from GenBank, three hLa mRNA-specific siRNAs
(siRNA1, siRNA2 and siRNA3) were designed using the web-
based tools from www.qiagen.com/siRNA and BLAST. A
negative control siRNA (siRNA4) was constructed with the same
nucleotide composition as the experimental siRNA but which
lacked significant sequence homology to the hLa, and its sequence
was confirmed by BLAST. Synthesis of siRNAs by in vitro
transcription of DNA templates was performed with the SilencerH
siRNA construction kit (Ambion, Austin, TX, USA), and the
transfection experiment was carried out with the RNAiFect
transfection reagent (Qiagen, Hilden, Germany). An electroche-
miluminescence method was used to detect HBeAg and HBsAg
levels in the supernatants of cells after siRNAs treatment [16].
From the above screening method, the most effective siRNA was
selected and transfected into HepG2.2.15 cells.
Western blotting and real time reverse transcription
(qRT-) PCR analysis. HepG2.2.15 cells were harvested from
15 cm plates (Falcon; BD Biosciences, Franklin Lakes, NJ, USA)
by using lysis buffer containing 20 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1.0% Triton-X-100, 0.5%
Nonidet P-40, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4,
1 mg/ml leupeptin, and 1 mM PMSF. Lysates were sonicated,
and protein concentrations were determined by BCA assay.
Proteins were resolved by 12% SDS-PAGE and transferred to
PVDF membranes (Roche Applied Science, Penzberg, Germany)
[24]. Membranes were blocked with 5% nonfat milk in Tris-
buffered saline Tween-20 (TBST) for 1 h, followed by an
overnight incubation at 4uC with the primary antibody of anti-
hLa (1:1000 in 1% nonfat milk, Abnova Corp., Taiwan). The next
day, membranes were washed with TBST and then incubated for
2 h with the secondary antibody of horseradish peroxidase (HRP)-
conjugated goat anti-mouse (1:1000; Bio-Rad, Hercules, CA,
Figure 4. Predicted binding modes of HBSC-11 (A), HBSC-15 (B) and HBSC-34 (C) compounds to the human La protein. The protein
surface is shown in gray. Oxygen atoms are shown in red and nitrogen atoms in blue. Carbon atoms of HBSC compounds and protein are shown in
cyan and gray, respectively. Crucial residues in the binding site are shown as sticks and labeled. Hydrogen bonds between HBSC compounds and
protein are depicted as yellow dotted lines. Figures were generated by PyMol.
doi:10.1371/journal.pone.0036363.g004
Figure 5. Chemical formulas and space structures of selected
compounds. Carbon atoms are shown in green. The hydrogen atom is
shown in white. Oxygen atoms are shown in red and nitrogen atoms in
blue. Compounds are shown as sticks and are labeled.
doi:10.1371/journal.pone.0036363.g005
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washed with TBST and immunoreactive bands were detected by
incubating with enhanced chemilluminescence reagents (ECL;
Amersham Biosciences, Piscataway, NJ, USA). Bands were
visualized by exposure to X-ray film (Eastman Kodak Co.,
Rochester, NY, USA), which was converted to a digital image
using a CanoScan N650U scanner (Cannon, New Holland, PA,
USA). Images were visualized in Adobe Photoshop CS.
For qRT-PCR analysis, isolated RNA (starting material, pellets,
and supernatants) was dissolved in 43 mL of diethyl pyrocarbo-
nate-treated water. Then, 5 mL of RNase-free DNase reaction
buffer and 2 units of RNase-free DNase (Promega, Madison, WI,
USA) were added, and the mixture was incubated for 30 min at
37uC. DNase was inactivated by heating the sample for 5 min at
72uC. Two mL of DNase-treated RNA was applied as template for
qRT-PCR. qRT-PCR was conducted with the Titan One-Tube
qRT-PCR kit (Roche Applied Science) and the following primer
pairs: La sense, 59-TGCTGTTTGTGAGCCTGTGGCG-39, and
anti-sense, 59-TCCCGTGGCAAATTGAAGTCGC-39; b-actin
sense, 59-AGAGCCTCGCCTTTGCCGATCC-39, and anti-
sense, 59-CTGGGCCTCGTCGCCCACATA-39. qRT-PCR
was performed with the same primers as those for standard RT-
PCR but on a LightCycler with Fast Start RNA Master SYBR
Green I reagents (Roche Diagnostics, Basel, Switzerland). The
thermal cycling protocol included an RT reaction at 61uC for
20 min, followed by denaturation at 95uC for 30 s and 40
amplification cycles of 95uC for 5 s, 60uC for 30 s, and 72uC for
10 s with a single fluorescence measurement. The melting curve
program was set at 60–95uC with a heating rate of 0.1uC per s
with continuous fluorescence measurement and a final cooling step
to 40uC. Negative control experiments that omitted the RT step or
used water instead of RNA yielded no products (data not shown).
Integrity of all reactions was confirmed by demonstration of
product melting curves with a melting point of 83uC and negligible
nonspecific products. In addition, gel electrophoresis and ethidium
bromide staining of aliquots of qRT-PCR products revealed that
correct-sized bands were the only products.
Statistical analysis. Results are presented as mean6SEM.
Statistical significance were analyzed using the Student’s t-test for
two groups and one-way analysis of variance for multi-group
comparisons. A P-value,0.05 was considered statistically
significant.
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